Based on multi-pathway induction of tumor immunogenic death and three-mode highly integrated strategy: a nanocomposite system loaded with irinotecan for colorectal cancer therapy

experiments showed that low-dose ICP@PDA-PP@HA NPs achieved a tumor inhibition rate of 95.8% after 21 days, and when combined with anti-PD-L1, the tumor inhibition rate reached 100% with no recurrence within 90 days.